

(12) INTERNATIONAL APP

ION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number
WO 01/04335 A2(51) International Patent Classification: C12N 15/86.
7/04, C07K 14/14, C12N 15/62, A61K 38/17

(21) International Application Number: PCT/US00/17755

(22) International Filing Date: 24 June 2000 (24.06.2000)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data: 60/143,132 9 July 1999 (09.07.1999) US

(71) Applicant (for all designated States except US): THE
GOVERNMENT OF THE UNITED STATES OF
AMERICA, as represented by THE DEPARTMENT
OF HEALTH AND HUMAN SERVICES [US/US]; 6011
Executive Blvd., Suite 325, Rockville, MD 20852 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BUCHHOLZ,
Ursula [DE/DE]; Boddenblick 10, D-17498 Insel Riems(DE). COLLINS, Peter, L. [US/US]; 12304 Village
Square #401, Rockville, MD 20852 (US). MURPHY,
Brian, R. [US/US]; 5410 Tuscawaras Road, Bethesda,
MD 20816 (US). WHITEHEAD, Stephen, S. [US/US];
7 Prairie Rose Lane, Gaithersburg, MD 20878 (US).
KREMPL, Christine, D. [DE/US]; 12512 Village Square
Terrace, Spt. 102, Rockville, MD 20852 (US).(74) Agents: KING, Jeffrey, J. et al.; Townsend and Townsend
and Crew LLP, Two Embarcadero Center, 8th floor, San
Francisco, CA 94111-3834 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: PRODUCTION OF ATTENUATED, HUMAN-BOVINE CHIMERIC RESPIRATORY SYNCYTIAL VIRUS VAC-
CINES

(57) Abstract: Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV "background" genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete "background" RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome. In preferred aspects of the invention, chimeric RSV incorporate a partial or complete bovine RSV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human RSV. Genes of interest include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment including a protein or portion thereof. A variety of additional mutations and

nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects.

WO 01/04335 A2